Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus,10.1007/s

Edit
Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus   (Citations: 1)
BibTex | RIS | RefWorks Download
The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1–6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.
Journal: Rheumatology International - RHEUMATOL INT , vol. 31, no. 6, pp. 757-763, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
More »
    • ...Tacrolimus is an immunosuppressive drug used for several autoimmune diseases, which inhibits the calcineurin pathway in T cells and reduces accompanying inflammatory cytokine production [3]...
    • ...Tacrolimus is a relatively new type of medication and has immunosuppressive effects [3]...
    • ...Suzuki et al. evaluated the efficacy and safety of tacrolimus in SLE, focusing especially on various lupus manifestations and found it to be effective for mild to moderate disease activity, including various manifestations of SLE [3]...

    Hiromi Kizu, et al. Improvement of irregularity of brain vessel walls in systemic lupus er...

Sort by:

Citations (1)

Share this on